基本信息
浏览量:0
职业迁徙
个人简介
Inge Marie Svane has more than 25 years of research experience in cancer immunology and immunotherapy and holds a PhD in basic cancer immunology. She has pioneered the field of cancer immunotherapy in Denmark, building up CCIT-DK, a translational research center in a leading European position. Her focus of expertise is T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation. CCIT-DK comprise a clean room (GMP) facility headed by Inge Marie Svane enabling manufacturing of in-house clinical grad immunotherapeutic products.
Since 2001 she has initiated more than 20 phase I, II, and III immunotherapeutic trials as academic sponsor. Further, she is national principal investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of immunotherapy. Inge Marie Svane is co-founder of IO Biotech, a spinout biotech company from Herlev and Gentofte Hospital and the Capital Region of Denmark aiming to develop immune modulating vaccines for cancer therapy. Inge Marie Svane has an extensive cooperative network with scientists and clinicians nationally and internationally and is a frequent speaker at national and international meetings, courses, and conferences.
Inge Marie Svane is key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. She actively supports the European cancer patient coalition as scientific committee member in the Immuno-Oncology Academy. She is member of the scientific committee and faculty on Immunotherapy in the European Society for Medical Oncology, ESMO. Further, she is initiator of a national, scientific network, IMMUNONET, member of the European melanoma group, EORTC, and steering group member of the Danish Melanoma Group heading national treatment guidelines and real-world patient registries.
Inge Marie Svane is co-author of more than 275 scientific publications, including senior author on more than 85 papers in NEJM, Lancet Oncol, Nature Med, Cancer Res, J Immunother Cancer, Br J Cancer, Clin Cancer Res, Oncoimmunology, Eur J Cancer, Cancer Immunol Immunother, Front Immunol, Cancer Immunol Res, and Blood a.o.
Since 2001 she has initiated more than 20 phase I, II, and III immunotherapeutic trials as academic sponsor. Further, she is national principal investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of immunotherapy. Inge Marie Svane is co-founder of IO Biotech, a spinout biotech company from Herlev and Gentofte Hospital and the Capital Region of Denmark aiming to develop immune modulating vaccines for cancer therapy. Inge Marie Svane has an extensive cooperative network with scientists and clinicians nationally and internationally and is a frequent speaker at national and international meetings, courses, and conferences.
Inge Marie Svane is key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. She actively supports the European cancer patient coalition as scientific committee member in the Immuno-Oncology Academy. She is member of the scientific committee and faculty on Immunotherapy in the European Society for Medical Oncology, ESMO. Further, she is initiator of a national, scientific network, IMMUNONET, member of the European melanoma group, EORTC, and steering group member of the Danish Melanoma Group heading national treatment guidelines and real-world patient registries.
Inge Marie Svane is co-author of more than 275 scientific publications, including senior author on more than 85 papers in NEJM, Lancet Oncol, Nature Med, Cancer Res, J Immunother Cancer, Br J Cancer, Clin Cancer Res, Oncoimmunology, Eur J Cancer, Cancer Immunol Immunother, Front Immunol, Cancer Immunol Res, and Blood a.o.
研究兴趣
论文共 508 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Stine K. Christensen, Mette L. Winther, Ida J. Laursen,Freja S. Madsen,Carsten Brink, Thomas H. Brix,Eva Ellebaek,Inge Marie Svane, Frederikke S. Hansen,Charlotte Haslund,Olivia K. Laursen,Henrik Schmidt,
SUPPORTIVE CARE IN CANCERno. 5 (2024)
Renske M. T. ten Ham,Maartje W. Rohaan,Inge Jedema,Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen,Cynthia Nijenhuis,Melanie Lindenberg,Troels Holz Borch, Tine Monberg,Marco Donia,
JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 3 (2024)
Liselotte Tas, Marie B. Weitemeyer,Maartje W. Rohaan, Troels H. Borch, Alexander C. J. van Akkooi,Michel W. J. M. Wouters,Koen J. Hartemink,Yvonne Schrage, Anke Kuijpers,Maaike Van Zon,Inge Jedema, Cynthia Nijenhuis,
ANNALS OF SURGICAL ONCOLOGYno. 1 (2024): S32-S32
引用0浏览0引用
0
0
Keith Henry Moss,Ulla Kring Hansen, Vinicius Araújo Barosa de Lima,Annie Borch, Esteban Sanchez Marquez,Anne-Mette Bjerregaard,Østrup Olga,Amalie Kai Bentzen,Andrea Marion Marquard, Mohammed kadivar,Inge Marie Svane,Ulrik Lassen,
crossref(2024)
Sif Homburg,Charlotte Birk Christensen,Magnus Pedersen, Simon Grund Sorensen,Marco Donia,Inge Marie Svane,Helle Westergren Hendel,Eva Ellebaek
CANCERSno. 5 (2024)
Stine K. Christensen, Mette L. Winther, Ida J. Laursen,Freja S. Madsen,Carsten Brink, Thomas H. Brix,Eva Ellebaek,Inge Marie Svane, Frederikke S. Hansen, Charlotte Haslund,Olivia K. Laursen,Henrik Schmidt,
Supportive Care in Cancerno. 5 (2024)
Signe Koggersbøl Skadborg, Simone Maarup,Arianna Draghi, Annie Borch, Sille Hendriksen,Filip Mundt, Vilde Pedersen, Matthias Mann,Ib Jarle Christensen,Jane Skjøth-Rasmussen,Christina Westmose Yde, Bjarne Winther Kristensen,
Cancer immunology research (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn